BPMC Quote, Financials, Valuation and Earnings

Agios Pharmaceuticals has a net margin of 0.33% compared to Blueprint Medicines's net margin of -1023.25%. Blueprint Medicines's return on equity of -49.13% beat Agios Pharmaceuticals's return on equity of 55.14%.

Blueprint Medicines has a consensus price target of $126.10, signalling upside risk potential of 29.77%. On the other hand Agios Pharmaceuticals has an analysts' consensus of $52.43 which suggests that it could grow by 91.91%. Given that Agios Pharmaceuticals has higher upside potential than Blueprint Medicines, analysts believe Agios Pharmaceuticals is more attractive than Blueprint Medicines.

Blueprint Medicines has a beta of 0.829, which suggesting that the stock is 17.117% less volatile than S&P 500. In comparison Agios Pharmaceuticals has a beta of 0.774, suggesting its less volatile than the S&P 500 by 22.618%.

Blueprint Medicines has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Agios Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Blueprint Medicines pays -- of its earnings as a dividend. Agios Pharmaceuticals pays out -- of its earnings as a dividend.

Blueprint Medicines quarterly revenues are $149.4M, which are larger than Agios Pharmaceuticals quarterly revenues of $8.7M. Blueprint Medicines's net income of $496K is higher than Agios Pharmaceuticals's net income of -$89.3M. Notably, Blueprint Medicines's price-to-earnings ratio is -- while Agios Pharmaceuticals's PE ratio is 2.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Blueprint Medicines is 11.08x versus 42.69x for Agios Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Alnylam Pharmaceuticals has a net margin of 0.33% compared to Blueprint Medicines's net margin of -9.67%. Blueprint Medicines's return on equity of -49.13% beat Alnylam Pharmaceuticals's return on equity of --.

Blueprint Medicines has a consensus price target of $126.10, signalling upside risk potential of 29.77%. On the other hand Alnylam Pharmaceuticals has an analysts' consensus of $320.56 which suggests that it could grow by 27.64%. Given that Blueprint Medicines has higher upside potential than Alnylam Pharmaceuticals, analysts believe Blueprint Medicines is more attractive than Alnylam Pharmaceuticals.

Blueprint Medicines has a beta of 0.829, which suggesting that the stock is 17.117% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals has a beta of 0.169, suggesting its less volatile than the S&P 500 by 83.104%.

Blueprint Medicines has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Blueprint Medicines pays -- of its earnings as a dividend. Alnylam Pharmaceuticals pays out -- of its earnings as a dividend.

Blueprint Medicines quarterly revenues are $149.4M, which are smaller than Alnylam Pharmaceuticals quarterly revenues of $594.2M. Blueprint Medicines's net income of $496K is higher than Alnylam Pharmaceuticals's net income of -$57.5M. Notably, Blueprint Medicines's price-to-earnings ratio is -- while Alnylam Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Blueprint Medicines is 11.08x versus 13.75x for Alnylam Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Arvinas has a net margin of 0.33% compared to Blueprint Medicines's net margin of 43.91%. Blueprint Medicines's return on equity of -49.13% beat Arvinas's return on equity of -7.72%.

Blueprint Medicines has a consensus price target of $126.10, signalling upside risk potential of 29.77%. On the other hand Arvinas has an analysts' consensus of $22.36 which suggests that it could grow by 238.29%. Given that Arvinas has higher upside potential than Blueprint Medicines, analysts believe Arvinas is more attractive than Blueprint Medicines.

Blueprint Medicines has a beta of 0.829, which suggesting that the stock is 17.117% less volatile than S&P 500. In comparison Arvinas has a beta of 2.215, suggesting its more volatile than the S&P 500 by 121.499%.

Blueprint Medicines has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arvinas offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Blueprint Medicines pays -- of its earnings as a dividend. Arvinas pays out -- of its earnings as a dividend.

Blueprint Medicines quarterly revenues are $149.4M, which are smaller than Arvinas quarterly revenues of $188.8M. Blueprint Medicines's net income of $496K is lower than Arvinas's net income of $82.9M. Notably, Blueprint Medicines's price-to-earnings ratio is -- while Arvinas's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Blueprint Medicines is 11.08x versus 1.12x for Arvinas. Usually stocks with elevated PS ratios are considered overvalued.

Amicus Therapeutics has a net margin of 0.33% compared to Blueprint Medicines's net margin of -17.31%. Blueprint Medicines's return on equity of -49.13% beat Amicus Therapeutics's return on equity of -17.7%.

Blueprint Medicines has a consensus price target of $126.10, signalling upside risk potential of 29.77%. On the other hand Amicus Therapeutics has an analysts' consensus of $15.82 which suggests that it could grow by 164.52%. Given that Amicus Therapeutics has higher upside potential than Blueprint Medicines, analysts believe Amicus Therapeutics is more attractive than Blueprint Medicines.

Blueprint Medicines has a beta of 0.829, which suggesting that the stock is 17.117% less volatile than S&P 500. In comparison Amicus Therapeutics has a beta of 0.640, suggesting its less volatile than the S&P 500 by 35.979%.

Blueprint Medicines has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Blueprint Medicines pays -- of its earnings as a dividend. Amicus Therapeutics pays out -- of its earnings as a dividend.

Blueprint Medicines quarterly revenues are $149.4M, which are larger than Amicus Therapeutics quarterly revenues of $125.2M. Blueprint Medicines's net income of $496K is higher than Amicus Therapeutics's net income of -$21.7M. Notably, Blueprint Medicines's price-to-earnings ratio is -- while Amicus Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Blueprint Medicines is 11.08x versus 3.36x for Amicus Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.